Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions

ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.

Major Capital Structure Optimization

Exousia Pro has successfully completed the cancellation of derivative securities convertible into 47 million shares of Common Stock. This substantial reduction was achieved through a strategic mediation and exchange agreement. In lieu of a prolonged legal dispute, the Company exchanged 2 million shares of LMMY for the cancellation of Series B Preferred shares (which were convertible into the 47 million common shares). As part of this transaction, Ludwig Enterprises, Inc. has entered into a formal lock-up and leak-out agreement regarding the LMMY shares, ensuring current and future market stability.

Telehealth Acquisition Momentum and Revenue Scaling

The Company is aggressively moving forward with Definitive Agreements to acquire three telehealth entities previously under Letter of Intent (LOI). Recent due diligence reveals exceptional growth:

• Revenue Growth: One target entity has scaled monthly revenue from $80,000 to $135,000 since December.
• Strategic Partnership: Beginning in April, this entity will serve as the exclusive supplier for 1,900 clinics. With an anticipated volume of 2,000 prescriptions per day at a rate of $4.00 per script, the Company anticipates a transformative impact on its consolidated revenue.

Commitment to Shareholder Value: Reg A & Buyback Program

Exousia Pro is currently utilizing a Regulation A offering to raise targeted capital for product launches and final testing. Management remains steadfast in its pledge to maintain a lean share structure. Upon reaching the funding goal of $200,000–$300,000, the Company intends to move to leverage its LMMY holdings and internal cash flow to fund a Share Buyback Program, thereby serving to neutralize any dilution resulting from the current offering.

Corporate Rebranding: Nextel Medical Corp.

Reflecting a new era of growth and a distinct market identity, the Company has filed for a name change with the State of Florida. The Company will transition from Exousia Pro, Inc. to Nextel Medical Corp. Shareholders may track the progress of this filing at www.sunbiz.org.